Company Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs.
The company’s clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.
It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.
The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation.
Oncternal Therapeutics, Inc. is headquartered in San Diego, California.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 30 |
| CEO | James Breitmeyer |
Contact Details
Address: 12230 El Camino Real, Suite 230 San Diego, California 92130 United States | |
| Phone | 858 434 1113 |
| Website | oncternal.com |
Stock Details
| Ticker Symbol | ONCT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001260990 |
| CUSIP Number | 68236P107 |
| ISIN Number | US68236P2065 |
| Employer ID | 62-1715807 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James B. Breitmeyer M.D., Ph.D. | President, Chief Executive Officer and Director |
| Richard G. Vincent CPA | Chief Financial Officer and Treasurer |
| Dr. Rajesh Krishnan Ph.D. | Chief Technical and Scientific Officer |
| Pablo Urbaneja | Senior Vice President of Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | 8-K | Current Report |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Oct 15, 2024 | 144 | Filing |
| Sep 12, 2024 | 8-K | Current Report |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| Jun 21, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| May 1, 2024 | EFFECT | Notice of Effectiveness |